[{"address1": "828 Winter Street", "address2": "Suite 300", "city": "Waltham", "state": "MA", "zip": "02451", "country": "United States", "phone": "857 524 2466", "website": "https://xiliotx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.", "fullTimeEmployees": 64, "companyOfficers": [{"maxAge": 1, "name": "Dr. Rene  Russo BCPS, Pharm.D.", "age": 49, "title": "President, CEO & Director", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 966228, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Frankenfield", "age": 42, "title": "CFO & COO", "yearBorn": 1982, "fiscalYear": 2024, "totalPay": 786196, "exercisedValue": 0, "unexercisedValue": 260}, {"maxAge": 1, "name": "Dr. Katarina  Luptakova M.D.", "age": 48, "title": "Chief Medical Officer", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 661890, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kevin M. Brennan", "age": 54, "title": "Senior Vice President of Finance & Accounting", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Uli  Bialucha Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nathan  McBride", "title": "Chief Information Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Caroline  Hensley", "title": "Chief Legal Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Scott  Coleman Ph.D.", "title": "Chief Development Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.7015, "open": 0.66, "dayLow": 0.66, "dayHigh": 0.7241, "regularMarketPreviousClose": 0.7015, "regularMarketOpen": 0.66, "regularMarketDayLow": 0.66, "regularMarketDayHigh": 0.7241, "payoutRatio": 0.0, "forwardPE": -1.2193104, "volume": 441463, "regularMarketVolume": 441463, "averageVolume": 753806, "averageVolume10days": 1180920, "averageDailyVolume10Day": 1180920, "bid": 0.6832, "ask": 0.7427, "bidSize": 3, "askSize": 6, "marketCap": 36653476, "fiftyTwoWeekLow": 0.615, "fiftyTwoWeekHigh": 1.7, "allTimeHigh": 27.95, "allTimeLow": 0.49, "priceToSalesTrailing12Months": 1.15248, "fiftyDayAverage": 0.78408, "twoHundredDayAverage": 0.769725, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -59372768, "profitMargins": -1.8390499, "floatShares": 23854049, "sharesOutstanding": 51829013, "sharesShort": 6156308, "sharesShortPriorMonth": 5162356, "sharesShortPreviousMonthDate": 1759190400, "dateShortInterest": 1761868800, "sharesPercentSharesOut": 0.1188, "heldPercentInsiders": 0.45122, "heldPercentInstitutions": 0.21722001, "shortRatio": 10.7, "shortPercentOfFloat": 0.1725, "impliedSharesOutstanding": 51829014, "bookValue": -0.156, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -58489000, "trailingEps": -0.7, "forwardEps": -0.58, "enterpriseToRevenue": -1.867, "enterpriseToEbitda": 1.408, "52WeekChange": -0.27263373, "SandP52WeekChange": 0.14261019, "quoteType": "EQUITY", "currentPrice": 0.7072, "targetHighPrice": 2.0, "targetLowPrice": 2.0, "targetMeanPrice": 2.0, "targetMedianPrice": 2.0, "recommendationMean": 1.0, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 1, "totalCash": 103764000, "totalCashPerShare": 1.976, "ebitda": -42182000, "totalDebt": 7263000, "quickRatio": 2.15, "currentRatio": 2.2, "totalRevenue": 31804000, "revenuePerShare": 0.614, "returnOnAssets": -0.26263002, "returnOnEquity": -9.0828495, "grossProfits": 53420000, "freeCashflow": -25476376, "operatingCashflow": -17151000, "revenueGrowth": 7.425, "grossMargins": 1.6796601, "ebitdaMargins": -1.3263099, "operatingMargins": -0.101169996, "financialCurrency": "USD", "symbol": "XLO", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Xilio Therapeutics, Inc.", "longName": "Xilio Therapeutics, Inc.", "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1763168346, "regularMarketTime": 1763154000, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1634909400000, "regularMarketChangePercent": 0.812543, "regularMarketPrice": 0.7072, "postMarketChangePercent": 1.7816749, "postMarketPrice": 0.7198, "postMarketChange": 0.012600005, "regularMarketChange": 0.00569999, "regularMarketDayRange": "0.66 - 0.7241", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 753806, "fiftyTwoWeekLowChange": 0.09219998, "fiftyTwoWeekLowChangePercent": 0.14991866, "fiftyTwoWeekRange": "0.615 - 1.7", "fiftyTwoWeekHighChange": -0.99280006, "fiftyTwoWeekHighChangePercent": -0.584, "fiftyTwoWeekChangePercent": -27.263372, "earningsTimestampStart": 1754479858, "earningsTimestampEnd": 1754911858, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.7, "epsForward": -0.58, "fiftyDayAverageChange": -0.07688004, "fiftyDayAverageChangePercent": -0.098051265, "twoHundredDayAverageChange": -0.062525034, "twoHundredDayAverageChangePercent": -0.08123035, "priceToBook": -4.5333333, "exchange": "NCM", "messageBoardId": "finmb_365333564", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-10-22", "averageAnalystRating": "1.0 - Strong Buy", "cryptoTradeable": false, "displayName": "Xilio Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-11-15"}]